ESR(01821.HK):两董事向主要股东OMERS购3,059万股股份
ESR(01821.HK)公布,Redwood Investment於今年12月15日订立买卖协议,以向公司主要股东OMERS Administration 收购3,058.71万股公司股份,占公司已发行股本约1%。买方分别由执行董事、联合创始人兼集团联席首席执行官Stuart Gibson以及执行董事、联合创始人兼集团总裁Charles Alexander Portes间接拥有50%及50%。预期收购事项将於2020年12月23日完成。
收购事项完成後,Stuart Gibson及Charles Alexander Portes持股将增至14.79%及14.79%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.